Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07487818 Nicotine Smoking Cessation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07487818 clinical trial report covering Nicotine, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07493785 Dexmedetomidine Hydrochloride Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07493785 clinical trial report covering Dexmedetomidine Hydrochloride, Phase 2/3, endpoints, sponsor, geography, readout timing and development white sp
Latest Hotspot
8 min read
NCT07490262 Bevacizumab biosimilar (Innovent Biologics) Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07490262 clinical trial report covering Bevacizumab biosimilar (Innovent Biologics), Phase 2/3, endpoints, sponsor, geography, readout timing and develo
Latest Hotspot
8 min read
NCT07490301 Telisotuzumab adizutecan Metastatic Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07490301 clinical trial report covering Telisotuzumab adizutecan, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07496567 Tiespectus Choroidal Neovascularization Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07496567 clinical trial report covering Tiespectus, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07502118 Talicabtagene autoleucel High grade B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07502118 clinical trial report covering Talicabtagene autoleucel, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07501507 Methotrexate Sodium Osteoarthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07501507 clinical trial report covering Methotrexate Sodium, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07504198 Rosuvastatin Calcium Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07504198 clinical trial report covering Rosuvastatin Calcium, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07383441 Ipilimumab Metastatic Clear Cell Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07383441 clinical trial report covering Ipilimumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07386938 Trastuzumab HER2 Positive Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07386938 clinical trial report covering Trastuzumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600118347 Flunotinib maleate Myelofibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
ChiCTR2600118347 clinical trial report covering Flunotinib maleate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07387367 Brincidofovir Adenovirus Infections, Human Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07387367 clinical trial report covering Brincidofovir, Phase 3, endpoints, sponsor, geography, readout timing and development white space.